RecruitingNCT06570902

Prospective WCD Post CABG Registry (CABG Registry)

Prospective WCD Post CABG Registry


Sponsor

Zoll Medical Corporation

Enrollment

910 participants

Start Date

Sep 23, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The primary objective is to observe the rate of recovery of ventricular function (EF\>35%) after first-time coronary artery bypass graft surgery in patients who were prescribed the wearable cardioverter defibrillator (WCD) post-surgery prior to being discharged after hospitalization as part of standard clinical care.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This registry study tracks patients who are prescribed a wearable cardioverter defibrillator (WCD) — a vest worn outside the body that can automatically deliver a shock to restart the heart if a life-threatening rhythm occurs — after coronary artery bypass graft (CABG) surgery. It focuses on patients with low heart pumping function (ejection fraction below 35%) who are at short-term risk of sudden cardiac death while recovering. **You may be eligible if:** - You recently had your first-ever CABG (bypass) surgery within the last 10 days - Your heart pumping function (ejection fraction) was found to be below 35% after surgery, before leaving the hospital - Your doctor prescribed the WCD vest for this reason - You are 18 or older **You may NOT be eligible if:** - You had valve repair surgery at the same time as bypass surgery - You have had a previous bypass surgery - You have an active single-chamber pacemaker - You have a physical or mental condition that prevents you from using the vest correctly - You have a do-not-resuscitate order or are in another interventional study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEWCD

An FDA-approved, CE marked WCD will be prescribed for up to 3 months of use after hospital discharge, with the option for longer use under physician discretion


Locations(4)

Kerckhoff Klinik

Bad Nauheim, Hesse, Germany

Medizinische Hochschule Hannover

Hanover, Lower Saxony, Germany

Sana-Herzzentrum Cottbus GmbH

Cottbus, Germany

Universitätsklinikum Halle (Saale)

Halle, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06570902


Related Trials